Best of the Week
Most Popular
1. The Trump Stock Market Trap May Be Triggered - Barry_M_Ferguson
2.Why are Central Banks Buying Gold and Dumping Dollars? - Richard_Mills
3.US China War - Thucydides Trap and gold - Richard_Mills
4.Gold Price Trend Forcast to End September 2019 - Nadeem_Walayat
5.Money Saving Kids Gardening Growing Giant Sunflowers Summer Fun - Anika_Walayat
6.US Dollar Breakdown Begins, Gold Price to Bolt Higher - Jim_Willie_CB
7.INTEL (INTC) Stock Investing to Profit From AI Machine Learning Boom - Nadeem_Walayat
8.Will Google AI Kill Us? Man vs Machine Intelligence - N_Walayat
9.US Prepares for Currency War with China - Richard_Mills
10.Gold Price Epochal Breakout Will Not Be Negated by a Correction - Clive Maund
Last 7 days
The Hottest Sports Stock Of 2020 - 23rd Sep 19
Stocks Wedge At The Edge – Front And Center - 23rd Sep 19
Stock Market Top Almost Confirmed - 23rd Sep 19
Thomas Cook COLLAPSE! 300,000 Passengers Stranded, Flights Cancelled, Planes Grounded - 23rd Sep 19
Massive Stock Market Price Reversion May Be Days or Weeks Away - 22nd Sep 19
How Russia Seized Control of the Uranium Market - 22nd Sep 19
Dow Stock Market Trend Forecast Update - 21st Sep 19
Is Stock Market Price Revaluation Event About To Happen? - 21st Sep 19
Gold Leads, Will the Rest Follow? - 21st Sep 19
Are Cowboys Really Dreaming of... Electric Trucks? - 21st Sep 19
Gold among Negative-Yielding Bonds - 20th Sep 19
Panicky Fed Flooding Overnight Markets with Cash - 20th Sep 19
Uber Stock Price Will Crash on November 6 - 20th Sep 19
Semiconductor Stocks Sector Market & Economic Leader - 20th Sep 19
Learning Artificial Intelligence - What is a Neural Network? - 20th Sep 19
Precious Metals Setting Up Another Momentum Base/Bottom - 20th Sep 19
Small Marketing Budget? No Problem! - 20th Sep 19
The Many Forex Trading Opportunities the Fed Day Has Dealt Us - 19th Sep 19
Fed Cuts Interest Rates and Gold Drops. Again - 19th Sep 19
Silver Still Cheap Relative to Gold, Trend Forecast Update Video - 19th Sep 19
Baby Boomers Are the Worst Investors in the World - 19th Sep 19
Your $1,229 FREE Tticket to Elliott Market Analysis & Trading Set-ups - 19th Sep 19
Is The Stock Market Other Shoe About To Drop With Fed News? - 19th Sep 19
Bitcoin Price 2019 Trend Current State - 18th Sep 19
No More Realtors… These Start-ups Will Buy Your House in Less than 20 Days - 18th Sep 19
Gold Bugs And Manipulation Theorists Unite – Another “Manipulation” Indictment - 18th Sep 19
Central Bankers' Desperate Grab for Power - 18th Sep 19
Oil Shock! Will War Drums, Inflation Fears Ignite Gold and Silver Markets? - 18th Sep 19
Importance Of Internal Rate Of Return For A Business - 18th Sep 19
Gold Bull Market Ultimate Upside Target - 17th Sep 19
Gold Spikes on the Saudi Oil Attacks: Can It Last? - 17th Sep 19
Stock Market VIX To Begin A New Uptrend and What it Means - 17th Sep 19
Philippines, China and US: Joint Exploration Vs Rearmament and Nuclear Weapons - 17th Sep 19
What Are The Real Upside Targets For Crude Oil Price Post Drone Attack? - 17th Sep 19
Curse of Technology Weapons - 17th Sep 19
Media Hypes Recession Whilst Trump Proposes a Tax on Savings - 17th Sep 19
Understanding Ways To Stretch Your Investments Further - 17th Sep 19
Trading Natural Gas As The Season Changes - 16th Sep 19
Cameco Crash, Uranium Sector Won’t Catch a break - 16th Sep 19
These Indicators Point to an Early 2020 Economic Downturn - 16th Sep 19
Gold When Global Insanity Prevails - 16th Sep 19
Stock Market Looking Toppy - 16th Sep 19
Is the Stocks Bull Market Nearing an End? - 16th Sep 19
US Stock Market Indexes Continue to Rally Within A Defined Range - 16th Sep 19
What If Gold Is NOT In A New Bull Market? - 16th Sep 19
A History Lesson For Pundits Who Don’t Believe Stocks Are Overvalued - 16th Sep 19
The Disconnect Between Millennials and Real Estate - 16th Sep 19
Tech Giants Will Crash in the Next Stock Market Downturn - 15th Sep 19
Will Draghi’s Swan Song Revive the Eurozone? And Gold? - 15th Sep 19
The Race to Depreciate Fiat Currencies Is Accelerating - 15th Sep 19
Can Crypto casino beat Hybrid casino - 15th Sep 19
British Pound GBP vs Brexit Chaos Timeline - 14th Sep 19
Recession 2020 Forecast : The New Risks & New Profits Of A Grand Experiment - 14th Sep 19
War Gaming the US-China Trade War - 14th Sep 19
Buying a Budgie, Parakeet for the First Time from a Pet Shop - Jollyes UK - 14th Sep 19
Crude Oil Price Setting Up For A Downside Price Rotation - 13th Sep 19
A “Looming” Recession Is a Gold Golden Opportunity - 13th Sep 19
Is 2019 Similar to 2007? What Does It Mean For Gold? - 13th Sep 19
How Did the Philippines Establish Itself as a World Leader in Call Centre Outsourcing? - 13th Sep 19
UK General Election Forecast 2019 - Betting Market Odds - 13th Sep 19
Energy Sector Reaches Key Low Point – Start Looking For The Next Move - 13th Sep 19
Weakening Shale Productivity "VERY Bullish" For Oil Prices - 13th Sep 19
Stock Market Dow to 38,000 by 2022 - 13th Sep 19 - readtheticker
Gold under NIRP? | Negative Interest Rates vs Bullion - 12th Sep 19
Land Rover Discovery Sport Brake Pads and Discs's Replace, Dealer Check and Cost - 12th Sep 19
Stock Market Crash Black Swan Event Set Up Sept 12th? - 12th Sep 19
Increased Pension Liabilities During the Coming Stock Market Crash - 12th Sep 19
Gold at Support: the Upcoming Move - 12th Sep 19
Precious Metals, US Dollar, Stocks – How It All Relates – Part II - 12th Sep 19

Market Oracle FREE Newsletter

How to Invest in the Esports Revolution

Is TamiFlu a Scam?

Politics / Global Pandemic Dec 08, 2009 - 11:47 AM GMT

By: Nadeem_Walayat

Politics

The NHS has spent more than £500 million on TamiFlu on the premise that it will prevent the transmission of flu and hospitalisation of Swine Flu patients. To help disburse millions of dosages costing £70 each, the NHS introduced a National Flu helpline during mid 2009 and an online service which has allowed millions of patients to obtain Tami-flu prescription authorisation after just a few mouse clicks.


However Channel 4 News is now reporting that the key paper on which the effectiveness of TamiFlu makers Roche claims are based are being questioned by scientists as the drug maker is apparently refusing to make the vital data available to scientists for peer review.

Channel 4 reports further that other studies on the efftiveness of Swine flu do not stand up to clinical research - New doubts over Tamiflu

Governments around the world stockpiled supplies. In the UK alone the estimated bill for Tamiflu is approaching half a billion pounds.

Tonight Channel 4 News can reveal that serious scientific questions are being raised over the evidence base for Tamiflu.

Scientists we have spoken to say they have been unable to judge and properly test some of the claims made about the antiviral by its makers, Roche.

Claims about the drug's effectiveness in reducing hospitalisations have been a key factor in decisions by governments around the world to stockpile Tamiflu (oseltamivir). Manufacturer Roche estimates that sales of Tamiflu this year will reach £1.6bn.

Tamiflu's benefits are well-publicised. Advocates say it reduces the chance of flu being transmitted in the first place, and that once someone has become infected it shortens the duration of the illness. Today's review confirms these findings.

But the drug is also credited with reducing complications and hospitalisations in those who develop full-blown flu. In a recent interview Roche Pharmaceuticals CEO William Burns said: "What Tamiflu can do is actually reduce hospitalisations by more than 60 per cent, which is really important if we are in the midst of a major pandemic."

This is the claim now under scrutiny. The investigation by Channel 4 News and the British Medical Journal (BMJ) has discovered that an independent team of scientists has been unable to verify the scientific evidence-base to support it.

The review, commissioned in July by the NHS and published today at BMJ.com, was conducted by the Cochrane Collaboration - a worldwide group of scientists and researchers that reviews medical research. They are internationally recognised for their work.

Speaking on Chanenl 4 News, Dr Tom Jefferson, one of the Cochrane reviewers said: "This is not just any drug, this is a public health drug which is recommended by governments...  and the World Health Organisation - and has been recommended for some years."

Much of the Cochrane team's work has looked at the leading piece of clinical research supporting claims that Tamiflu reduces hospitalisations. This research was authored by swiss scientist Professor Laurent Kaiser.

His research, based on 10 clinical trials set up by Roche found that Tamiflu reduced by 59 per cent the number of people with flu who ended up in hospital. Roche have repeatedly referred to Professor Kaiser's paper when talking about Tamiflu's ability to reduce hospitalisations.

The study released today acknowledges that Tamiflu has a modest effect in reducing symptoms and duration of illness in otherwise healthy adults by about one day, but says there is insufficient published data to independently confirm  its effects on reducing complications leading to hospitalisations .

When the Cochrane reviewers approached Professor Kaiser for the original data in order to verify his conclusions, he said he didn't have it and referred them to  Roche. However, following detailed communication with the company, Roche did not supply the Cochrane team with the complete data they had requested and they were unable to verify the paper's findings.

Because they were unable to independently verify this data, the Cochrane review disregarded Kaiser’s paper from their analysis of the scientific evidence base supporting Tamiflu’s effectiveness in reducing complications.  This removes a key plank of evidence supporting a claim repeatedly made by Roche and governments like ours.

And without this study, the reviewers came to a stark conclusion. Dr Jefferson told Channel 4 News: "We didn't find any convincing evidence that Tamiflu affects complications such as as hospitalisations and chest infections."

Source:

By Nadeem Walayat
http://www.marketoracle.co.uk

Copyright © 2005-09 Marketoracle.co.uk (Market Oracle Ltd). All rights reserved.

Nadeem Walayat has over 20 years experience of trading derivatives, portfolio management and analysing the financial markets, including one of few who both anticipated and Beat the 1987 Crash. Nadeem's forward looking analysis specialises on the housing market and interest rates. Nadeem is the Editor of The Market Oracle, a FREE Daily Financial Markets Analysis & Forecasting online publication. We present in-depth analysis from over 400 experienced analysts on a range of views of the probable direction of the financial markets. Thus enabling our readers to arrive at an informed opinion on future market direction. http://www.marketoracle.co.uk

Disclaimer: The above is a matter of opinion provided for general information purposes only and is not intended as investment advice. Information and analysis above are derived from sources and utilising methods believed to be reliable, but we cannot accept responsibility for any trading losses you may incur as a result of this analysis. Individuals should consult with their personal financial advisors before engaging in any trading activities.

Nadeem Walayat Archive

© 2005-2019 http://www.MarketOracle.co.uk - The Market Oracle is a FREE Daily Financial Markets Analysis & Forecasting online publication.


Post Comment

Only logged in users are allowed to post comments. Register/ Log in

6 Critical Money Making Rules